Wang et al. (30, 81) demonstrated that S1P blockade improved Ang II-induced hypertension by decreasing the activation of ENaC and AQP2 in the kidney, and this effect was reversed by intravenous administration of recombinant sPRR. The gene discussed is AGT; the disease is hypertensive disorder.